VC
EPRX

Vivo Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Vivo Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.92M Hold
1,350,000
– – 0.81% 30
2026
Q1 		$9.77M Hold
1,350,000
– – 0.81% 32
2025
Q4 		$10.2M Hold
1,350,000
– – 0.66% 34
2025
Q3 		$7.96M Buy
+1,350,000
New +$7.35M 0.64% 35

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vivo Capital's EPRX Position: Q2 2026 in Review

Vivo Capital held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 1,350,000 shares worth $8.92M. The position accounts for 0.81% of the portfolio, ranked #30.

Vivo Capital first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.2M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Vivo Capital held 1,350,000 shares of Eupraxia Pharmaceuticals worth $8.92M as of Q2 2026.
  • Vivo Capital left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up 0.81% of Vivo Capital's portfolio in Q2 2026, its #30 holding.
  • Vivo Capital first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Vivo Capital's Eupraxia Pharmaceuticals position peaked at $10.2M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.